Anti-tumor efficacy was enhanced with IL-13Rα2 DNA priming plus a protein/adjuvant boost consisting of the extracellular domain of IL-13Rα2 protein, CpG, and incomplete Freund’s adjuvant (IFA) (103). The gene discussed is IL13RA2; the disease is neoplasm.